Abstract
This report aims to assess the indication for pulmonary arterial hypertension (PAH). Adempas® (riociguat) is indicated for pulmonary arterial hypertension treatment in adult patients on monotherapy or in combination with endothelin receptor antagonists with functional class II to III of WHO (World Health Organization) to improve exercise capacity. It has been shown the efficacy in hereditary or idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with connective tissue disorders.
Keywords
Arterial hypertension; Riociguat; Assessment
Bibliographic citation
Comitè d’Avaluació de Medicaments d’Ús Hospitalari (CAMUH). Riociguat (Adempas®) per al tractament de la hipertensió arterial pulmonar. Barcelona: Agència de Qualitat i Avaluació Sanitàries de Catalunya; 2015. (Informes CAMUH).
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/2435This item appears in following collections
The following license files are associated with this item: